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Correspondence between stone composition and urine supersaturation
in nephrolithiasis. Supersaturation (SS) with respect to calcium oxalate
monohydrate (COM), brushite (Br) and uric acid (UA), obtained in three
24-hour pretreatment urine samples from patients with stone disease were
compared to the mineral composition of stones passed by the same
patients to determine whether sparse urine SS measurements accurately
reflect the long-term average SS values in the kidney and final urine.
Among males and females elevation of SS above same sex normals
corresponded to composition. As well, treatments that reduced stone rates
also reduced these SS values. The degree of calcium phosphate (CaP)
admixture was accurately matched by shifting magnitudes of COM and Br
SS. As well, increasing CaP content was associated with falling urine
citrate and rising urine pH, suggesting renal tubular acidosis. We conclude
that sparse urine SS measurements accurately track stone admixtures, and
are a reliable index of average renal and urine SS.
Supersaturation (SS), the presence of a material in solution at
a concentration above its own solubility [1], is the driving force for
crystal formation [2]. Relevant SS for the majority of human
stones include calcium oxalate monohydrate (COM), calcium
phosphate phases such as brushite (Br) and octocalcium phos-
phate, uric acid (UA), and struvite. We neglected struvite in this
study, as it concerns only stones of infectious origin [31, and
considered Br as the main CaP phase [4]. So-called 'calcium'
stones are usually made predominantly of CaOx [5], but a majority
also contain CaP, mainly as apatite. COM, Br, and UA SS values
can be calculated in human urine samples using measurements of
pertinent ligands [6], and directly measured by adding crystals to
urine aliquots and determining the fall in relevant ion concentra-
tions [7]. We [8—12] and others have presented such measure-
ments, and generally have found elevated SS values in stone
forming patients compared to normal people. One epidemiolog-
ical study found SS to he among the principal factors that
discriminate between stone forming and non-stone forming mem-
bers of a study group [13].
An open question with regard to SS measurements is how well
a sparse sample, of perhaps three pretreatment 24-hour urine
collections, can represent the average SS present over the months
to years during which stones form and grow. Diet, habits, change
in work all would be expected to alter SS averages over the
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considerable time scale of stone production. Possibly, urine SS
fails to reflect important SS values in the nephron because of
heterogeneity. For example, we have presented evidence for a
constant calcium phosphate SS in the thin segment of Henle's
loop [14] that has no necessary counterpart in urine SS. Factors in
the nephron, such as nucleating sites [15—18], and inhibitors or
promoters [19, 20] affect crystallization. These may so overweigh
SS effects that variations of urine SS are not well linked to stone
composition. Finally, Br SS may not fully reflect forces for
production of phosphate phases in stones, which are mainly
apatite.
Fortunately, the stones themselves offer a strategy for assessing
this question. The stone composition should reflect the SS aver-
ages during the creation and growth of the stone, so the stone is
a kind of geological artifact of SS conditions. If sparse urine
samples are representative, their measured SS values should
parallel the phase compositions of the stones actually formed and
passed by the patients who provide those urine samples. If such a
parallel cannot be found, the hypothesis that sparse samples
reflect average nephron conditions should be rejected. We
present here the comparison of urine SS and stone admixtures
among a large group of patients, as a critical test of the sparse
urine sample hypothesis.
Methods
Patients and normal subjects
From our total of 1085 patients with crystallographic analyses of
stones, we selected those with no systemic cause of stones such as
hyperparathyroidism, enteric disease, laxative abuse, or cystinuria.
We also excluded patients whose stones contained any struvite or
any unusual material, such as sodium, potassium or ammonium
urate, or crystallized drug. This left 585 patients. Each had been
evaluated prior to treatment with SS measurements, and had
formed stones that fell into one of five discrete groups: (1) CaOx
stones, defined as > 80% calcium oxalate in the average of all
stones, less than 20% calcium phosphate in the average of all such
stones that contain any calcium phosphate, and no uric acid in any
stone (316 males and 85 females); (2) CaP stones, > 50% calcium
phosphate average for all stones, no uric acid, < 50% calcium
oxalate for the average of all stones that contained calcium
oxalate (19 males and 24 females); (3) UA stones, all stones
contained only uric acid (11 males and 3 females); (4) mixed
(calcium oxalate uric acid) stones, both crystals in stones, in any
amounts (67 males and 12 females); (5) CaP/CaOx stones,
calcium oxalate content above 0 and calcium phosphate
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Table 1. Urine supersaturations in stone forming patients and controls
Type Sex
N
C RX
COM SS Br SS UA
-
SS
C RX C RX C RX
Normal Men 65 — 8.4 0.52 1.71 0.17 — 1.33 0.14 —
CAOX
Women
Men
54
935
—
1934
6.66 0.45 — 1.12 0.16
1.62 0.04
—
1.27 0.02"'
1.01 0.13
1.32 0.04
—
0.61 0.02'9.28 0.16 5.75 Oöfl
CAP
Women
Men
254
58
479
102
0.34" 5.27 15" 1.60 0.08" 1.10 004" 1.43 0.08"
0.51 0.09"
0.47 0.03"'
0.11 0.01'8.80 0.57 5.36 0.34" 2.41 0.13" 1.81 0.09" I
Uric acid
Women
Men
69
33
154
58
7.68 0.52
5.02 0.54"
4.45 0.27"'
4.52 0.36a
1.96 0.14" 1.45 0.09 0.55 0.08" 0.18 002ad
0.45 0.08 0.65 0.09" 1.84 0.24" 1.14 0.141
Mixed
Women
Men
9
190
17
390
8.02 2.3 3.60 0.40 0.622 0.09
0.73 0.06"
1.12 0.16
1.00 0.05"'
2.03 0.48"
2.34 0.09"
0.45 0.14'
1.13 0.06"8.68 0.34 5.97 0.17"'
Women 36 88 9.22 0.70' 6.42 0.42" 1.02 0.16 1.12 0.09 1.79 0.18" 0.77 0.08J
Values are SS SEM. Type is type of stones formed (Methods) Abbreviations are: N, number of samples provided by subjects in the group specified;
C, pretreatment, RX, during treatment samples; COM, Br and UA are calcium oxalate, calcium phosphate, and uric acid supersaturations, respectively
(Methods); UA SS in CaP stone formers, COM SS in male VA stone formers, Br SS in UA and Mixed stone formers all are significantly below
corresponding same sex controls.
Differs from same sex normal < 0.001, " P < 0.01, "P < 0.05
"Differs from pretreatment, same sex, P < .001, "P < 0.01
content > 20% and < 50%, no uric acid (31 males and 19
females). Our control group was comprised of 67 non-stone
forming people (33 males and 34 females).
All patients were studied using a protocol based on three
24-hour urines with three corresponding blood samples drawn 12
hours after the last meal [9]. Stone prevention was also based
upon a protocol detailed elsewhere [21, 22], which aimed at
reversing the main nonsystemic causes of stones: idiopathic
hypercalciuria, hypocitraturia, hyperoxaluria, hyperuricosuria,
and low urine volume and pH. During treatment, 24 hour urines
and corresponding blood samples were obtained at about six
weeks, and yearly thereafter, to monitor treatment. Because this
facility is a referral center, virtually all patients were active stone
formers at the time of their initial evaluation. In general, referral
was created by a recent stone or procedure, and stone rates were
often higher near to the time of referral than in the past history of
the patients.
Stones were analyzed by routine commercial laboratories. We
added the % values for calcium oxalate monohydrate and dihy-
drate to obtain the % CaOx value for a stone, and added all
phases of calcium phosphate together, in the same manner, to
obtain the %CaP. Phases included apatite, brushite, and octocal-
cium phosphate. For uric acid, we took the % as noted.
Laboratoiy measurements and calculations of SS
In urine we measured calcium, phosphate, creatinine, uric acid,
magnesium, sodium, potassium, pH, volume, citrate, oxalate,
sulfate, chloride, and ammonium ion. From this set of urine
measurements SS was calculated with respect to calcium oxalate
monohydrate, brushite, and undissociated uric acid using the
software program EQUIL [6].
Statistical methods
SS values among patients and normals were compared using
contrasts in the general linear model [23]. Essentially, this is a
multivariate analysis of variance. Some comparisons were done
with urine volume as the covariate, to permit assessing differences
in SS holding volume to the joint mean of comparison groups. In
this, SS was the dependent variable, volume the independent
variable, and the group as defined by stone type was the grouping
variable. For presentation, we calculated means, and the standard
error (sEM) for all SS values by sex and stone type. For all analyses
all SS values were transformed by square root to achieve normal-
ity. The distribution of the square roots of a set of numbers is
often more normal in its distribution than the parent distribution,
as was the case here. We performed the contrasts two ways:
sample based, using all 24-hour urine samples from each group
and normals, and subject based, using either pretreatment or
treatment means from each patient. Sample based analysis
weighted individuals by their numbers of samples, whereas subject
based means that each individual contributed equally to the
subject based means. Volume adjustment was applied only in
comparisons of patient pretreatment results to sex-matched nor-
mal subjects; all treatment comparisons to either normals or
pretreatment used no covariates because treatment includes a
deliberate increase of urine volume, to reduce SS, whereas
pretreatment values reflect the actual ambient hydration during
active stone formation.
We performed our analyses by first excluding Group 5, as
defined above. This was to achieve a sense of SS correspondence
with stone phases at the extremes of composition. We then
performed a separate and more detailed analysis of CaP admix-
ture, in which Group 5 was considered along with Groups 1 and 2.
For this, Groups 3 and 4 were omitted, because uric acid forms at
relatively low urine pH values, and uric acid stones have little if
any CaP phases in them.
Results
Sample based analysis, Groups I to 4
Our main hypothesis is that significant SS elevations should
occur mainly in the boxed regions of Table 1, whose cells
represent the matching of SS and crystal composition. The
prediction is, in part, fulfilled. Pretreatment SS is high for women
in all cells (lower rows in boxed regions). Men were the same,
except for COM SS that was not above normal in patients with
either CaOx stones or mixed stones (upper rows in boxed areas).
There were no significant elevations of SS outside the boxes,
except among women with CaOx stones who had high Br and Ua
SS. All other significant departures of SS from normal were in a
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Fig. 1. A. Male stone formers plotted on the three SS axes. Actual SS values
and P values for comparisons are in Table 1. For the CaPICaOx group
values and comparisons are in the text (Results). The groups represented
by the descriptive labels are: CaOx, Group 1; CaP, Group 2; UA, Group
3; Mixed, Group 4; CaP/CaOx, Group 5. B. Female stone formers plotted
on the three SS axes. Actual SS values and P values for comparisons are
in Table 1. For the CaP/CaOx group values and comparisons are in the
text (Results). Labels and groups as in Figure 1A.
downward direction, as one would expect from the mismatch of SS
to stone crystal composition (Table 1).
If visualized along the three SS coordinates of Table I (Fig. 1),
stone formers segregated to the SS regions appropriate to their
stone composition group. The remarkable difference in SS be-
tween normal women and normal men (P < 0.001) is best seen by
comparing Figure 1 a and b. Urine volumes of men with CaOx and
CaP stones exceeded the volumes of normal men (Table 2),
whereas for women the opposite was true as urine volumes were
below normal for those with CaOx, Ua and mixed stones. An SS
that is above normal in relation to urine volume would lead to a
corresponding elevation of SS above normal whenever urine
volume passes through normal. SS comparisons of patients and
normals using ANOVA with volume as covariate (Table 2) were
the same as for unadjusted SS, except that men and women alike
displayed high SS values that corresponded to their stone com-
positions (boxed areas). The exceptions were patients with CaP
stones who had elevated COM SS elevations, men with mixed
stones who did not have elevated COM SS, and the three women
with UA stones whose Ua SS elevation did not reach significance.
Treatments reduced stone relapse among those patients with
follow-up data. Relapse occurred in 42 males with calcium oxalate
stones, 3 with CaP stones, none with uric acid stones, and 8 with
mixed stones, or 17%, 20%, 0% and 15%, respectively (total
numbers of patients in Methods). Among women, corresponding
values were 9, 5, 0, and 0, or 13%, 26%, 0%, and 0%, respectively.
Overall, only 16% of men and 14% of women relapsed. These
results have been detailed elsewhere, and occurred over long
periods of treatment 24, 25]. One would expect that such effective
treatment would act through reduced SS, and such a reduction
was very evident in all groups (Table 1 and Fig. 1). Relevant SS
was reduced to or below normal (boxed areas), except for Br SS
among women with CaP stones. As well, values of SS were
reduced compared to pretreatment (Table 1 and Fig. 1). In other
words, treatment reduced SS greatly, in relation to both normal
and pretreatment values, and in the direction required to reduce
formation of the relevant solid phases for each group.
Subject based analysis, Groups 1 to 4
Because patients provided three samples pretreatment versus
one or two for each normal person, and because during treatment
patients provided widely differing numbers of samples, we repre-
sented each patient by the mean of all pretreatment and treat-
ment values, and each normal person by the average of all
samples. Our main hypothesis, that significant SS elevations will
occur mainly in the boxed areas of Table 3, was still supported
except for the mixed stone formers. In fact, there were no
significant SS elevations outside those areas except for COM SS in
CaP stone formers. Treatment reduced SS corresponding to stone
type in all instances except male CAP stone formers (Table 4).
Other reductions of SS unrelated to stone type also occurred, but
this neither supports nor opposes our basic hypothesis; effective
treatments reduced relevant SS values. The correspondence of
subject and sample centered contrasts, especially in treatment
comparisons, shows that patients with large numbers of samples
did not importantly bias the sample based comparisons.
Admixture and SS, Groups 1, 2 and 5
Our analysis has thus far relied on exclusion of the middle, with
respect to calcium phosphate admixturcs with calcium oxalate.
However, an implicit prediction of our main hypothesis is that the
excluded middle group of patients (Group 5, Methods) should
show triple coordinates for SS between the locations of Groups 1
and 2. This middle group, with stones that contain between 20 and
50% calcium phosphate, should show SS values midway between
those of the predominant calcium oxalate stone formers and those
patients whose stones are above 50% calcium phosphate. This is
in fact the case (Fig. 1 a, b). The critical COM and Br SS values
(Fig. 2) show a close correspondence with increasing CaP admix-
ture among women, and a similar pattern among men but
compressed in scale because the dynamic range of SS was smaller.
Mean 24-hour urine pH values rose progressively with CaP
admixture, being slightly below normal among Group I patients,
A
12.25
9.00
Cl)
Cl)
I 6.25
c-
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Table 2. Volume adjusted values of supersaturation
Sex
Volume
Patient
CoM SS Br SS UA SS
Normal Patient Normal Patient Normal Patient
—
CAOX M 1.64 0.024" 7.54 0.52 9.33 0.14" 1.53 0.14 1.64 0.04 1.13 0.13 1.34 0.034
CAP
W
M
1.27 0.04"
1.855 0.09"
7.56 0.60 10.15 0.2r' 1.26 0.17 1.57 0.08 1.22 0.15
1.19 0.11
1.38 0.07
0.664 0.12°7.83 0.51 947 0.54 1.56 0.14 2.58 0.15"
UA
W
M
1.75 0.1
1.77 0.17
6.39 0.46
8.13 0.46
7.884 0.41°
5.58 0.62"
1.07 0.15 1.99 0.13" 0.96 0.1 0.594 0.08
1.67 0.14 0.52 0.18" 1.2 0.14 2.06 0.19
Mixed
W
M
W
1.08 0.14'
1.39 0.034
1.25 0.086c
6.81 0.51 7.16 1.26 1.169 0.13
1.69 0.12
1.22 0.13
0.315 0.33
0.729 0.069
0.87 0.16
1.05 0.13
1.28 0.13
1.09 0.13
1.74 0.32
2.37 0.078a
1.67 0.15°
8.28 0.53
0.42
8.68 0.311
8.63 0.52
Urine volumes for normal men and women, respectively are 1.33 0.49 and 1.56 0.10 liter/day. Values are volume adjusted SEM, except volumes,
which are actual values. Abbreviations are in Table 1, except that M and W are men and women, respectively.
"Differs from normal, same sex, P < 0.001; bP < 0.01; "P < 0.05
Table 3. Subject centered SS comparisons between patients and
normals
UA
Stone Sex N COM SS Br SS SS
CAOX M 316
F 85
CAP M
F
19
24
UA M
F
11
3
Mixed M
F
67
12
IO.oolb I 0.12 0.03"
o.ooi"I 0.07 0.22
0.028" 0001" I 0.012"
0.024" 0.001" 0.o50
b ><0.009" o.OOla 10.004 o
0.64 0.22 0.20 E[ö1 o.oola 0001b
0.43 003h j
C)
C,)
C,)
P values are from contrasts in the linear model (Methods). All high SS
values are in boxed areas of corresponding SS and stone type except for
COM SS in CAP Stone forming women.
"Below normal SS
b Above normal SS
Table 4. Subject centered SS comparisons between untreated and
treated patients
Stone Sex N COM SS
Br
SS
UA
SS
CAOX M
F
243
68
0.001
0.001
0.006
0.002
0.001
0.001
CAP M
F
15
19
0.025
0.001
0.119
0.001
0.716
0.779
UA M
F
10
2
0.79
0.22
0.209
0.297
0.027
0.026
Mixed M
F
53
11
0.001
0.003
0.152
0.392
0.001
0.024
P values from contrasts in linear model (Methods); all significant
changes were in a downward direction. SS values in all boxed areas of
corresponding SS and Stone type fell except fur Br SS in men CAP stone
formers; other reductions of SS also occurred as noted.
1.0 1.5 2.0 2.5
SS brushite
Fig. 2. Male and female patients plotted along their CaOx and CaP
supersaturation axes. Stone groups are defined in the Methods section.
Labels and groups are as in Figure 1. COM SS Groups 1, 2, and 5 versus
normal, P values were all not significant except for females in Groups 1
and 5 (P < 0.001). For Br SS Groups 1, 2, and 5 versus normal, P values
were all < 0.01 except for men in Group 1 (NS).
11
10
9
8
7
6
•F CaP/CaOX
F CaOX•
M CaP/CaOX
M CaOX i
M CaPt
M normal
• F CaP
• F normal
and above normal in Groups 2 and 5 (Fig. 3). Urine citrate
concentration fell as pH rose (Fig. 3). All differences between
groups by sex were significant except as noted in the legend to
Figure 3. In other words, at least these two critical determinants of
Br SS, pH and citrate, varied in a direction to raise it in patients
whose stones were enriched with CaP (Fig. 3). The other main
determinants of Br SS, calcium, oxalate, and phosphate excretions
and concentrations did not differ between the relevant groups
under discussion except for higher calcium excretion among
women in Groups 2 and 5 compared to women in Group 1 (not
shown). Urine volumes in Group 5 did not differ from normal or
the other groups, except for women (Group 5, 1.38 liter/day vs.
Group 2, Table 2; P < 0.05).
Discussion
Our findings strongly support the hypothesis that urine COM,
Br, and UA SS, as measured in three 24-hour outpatient urine
collections, closely reflect the average driving forces in the
nephron that control formation of the solid phases of kidney
stones. Even though stones themselves are widely spaced in time,
and probably grow over months to even years, SS in our three
urine samples closely matchs the admixtures of CaOx, CaP and
UA in the stones. Since stones should reflect the integrated time
average of SS values in tubule fluid and urine, this close matching
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have high COM SS values compared to normal women. Normal
male COM SS values are about those of male patients, whatever
the CaP or UA admixture of their stones. Normal female COM SS
0 F normal values, however, are remarkably lower than among patients or
normal males. This difference may well be the primary reason that
nearly 80% of stone formers are men [24]. In part, the lack of a
M normal clear male patient COM SS elevation above male normals isF CaOX because males with CaOx stones have higher urine volumes than
normal men. When volume is used as a covariate, COM SS of
• male stone formers is decisively above normal male SS, meaning
M CaOX 0 F CaPICaOX that variations of urine volume through the normal range, from
ordinary effects of diet, habit, and environment, pose a greater
stone risk. In a well known study [44], high SS values for CaOx and
• A M CaP/CaOX CaP were clearly demonstrated in patients with stones. Of inter-
est, the control group was half female whereas the stone groups
F
were about 70% male.• a The high urine volume of male stone formers is not of an
M CaP obvious origin. Perhaps men, but not women, are given, and heed,
I A advice to drink more water as a stone prevention. This seems a bit
unlikely. Men with mixed CaOx/UA stones do not have higher
volumes, as women do not. Our patients are referred here because
of active stone disease and therefore the initial evaluation data,
which show the high male urine volumes, are taken from active
stone formers. Perhaps hypercalciuria or some other mechanism
reduces the urine concentrating power among men.
Our treatment protocol results in a low frequency of relapse
(Results). One would expect that SS should fall with such
treatments to at least the levels seen in normals. Among men and
women, SS fell significantly compared to pretreatment. SS did not
always fall below normal, but was no higher than normal except
among women with CaP stones (Table 1). This fact, coupled with
the fall in stones, is consistent with the idea that SS is a main but
not sole factor in stone production. Inhibitors, promoters, and
local nucleation and adhesion sites are well known and much
studied additional factors [45—48].
Prior studies from this laboratory are fully compatible with the
present one. Using crystal addition, we [8] found higher COM SS
among patients who had formed at least one calcium stone,
without uric acid. SS fell with treatment. Among patients with at
least one calcium stone and hyperuricosuria, we [10] found high
SS with respect to sodium hydrogen urate and uric acid, which
suggested a role for uric acid crystallization in calcium stone
production. Among patients with over 10 calcium stones per
person, we failed to find abnormal COM SS, perhaps because
such patients had only modest hypercalciuria [49]. Using crystal
addition, we have in the past found higher COM SS among
normal men than normal women, and a corresponding elevation
of SS among women stone formers compared to normal women,
with a lack of such an elevation among men with stones, who also
were found to have a higher than normal urine volume [9]. Given
the many years that separate our two studies, the correspondence
of findings is impressive to us. We have also found high COM and
Br SS in pregnancy resulting from pregnancy hypercalciuria,
increased urine pH, and a failure of urine citrate to rise in a
manner appropriate to rising urine pH [26]. We [50] have found
that patients with mixed CaOx/UA stones exhibit elevation of
both COM and UA SS, whereas patients who formed pure UA
stones had more marked UA SS.
Large numbers of studies by other laboratories have shown high
SS values in stone formers, with a reduction in COM and Br SS by
0
E
1)
cci
0
ci)C
D
3.0
2.5
2.0
1.5
1.0
5.90 6.02 6.14 6.26 6.38 6.50
Urine pH
Fig. 3. Relationship between urine citrate concentration and pH. Male and
female stone groups are defined in the Methods section. Symbols are:
males, triangles; females, circles; open are normals; light gray, the CaOx
group; darker gray, the CaP/CaOx group; and solid symbols are CaP. CaP
patients differed from all other groups, by sex, in both citrate and pH, P <
0.01 all comparisons. CaP/CaOx differed from CaOx and normal except
for males versus normals in pH, and females versus CaOx in citrate and
pH. CaOx differed from normal only in citrate, P < 0.05 and < 0.001,
females and males, respectively. Labels and groups are in Figure 1.
validates the use of urine samples as a strong indicator of the
average conditions that produce stones.
In the case of CaP admixture, our results demonstrate a
surprising degree of predictive value for SS. When patients were
divided into Groups 1, 2 and 5, representing variable degrees of
CaP admixture, we found close correspondence between the
balance of COM SS and Br SS and stone admixture, especially
among women. The pattern among men was the same but
miniaturized in dynamic scale along the COM SS axis because
normal men have high COM SS compared to normal women. We
were able to find at least part of the mechanisms for high Br SS in
a surprising inverse correlation between urine pH and citrate.
Elsewhere, we [26] have shown that urine citrate rises greatly with
alkali, in agreement with others [27—33]. In pregnancy [26], we
found a rise of urine citrate with urine pH, though less marked
than among nonpregnant women [26]. The renal basis for the
inverse correlation shown here is unknown. However, it suggests
common hut mild renal tubular acidosis among patients with even
modest CaP admixtures.
Uric acid admixtures also showed an excellent correlation
between SS and composition. However, mixed CaOxJUA stone
formers of both sexes do not have higher than normal COM SS.
Possibly, the CaOx component of their stones is due to an
interaction between uric acid crystallization and CaOx crystalliza-
tion, such as has been explored in the hyperuricosuria calcium
oxalate nephrolithiasis complex [15, 24, 34—43]. This could permit
COM to develop even without a remarkable increase of COM SS.
We have found, in the course of this work, that normal men
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treatments that include water [121, medications [11, 40, 51—60],
and altered diet sodium or acid [61, 62]. Simplified approxima-
tions to calculated SS have been extensively validated and show a
pattern of higher values among patients than normal subjects [1,
63]. Finally, in a population study, Thun and Schober [13] found
that COM SS values strongly correlated with the risk of stone
formation, with family history being the other main correlate.
All of these are consistent with this study, which adds to them
the correspondences between measured SS and stone composi-
tions, and the important sex differences not always clear in other
studies. These new additions represent a critical test of the
hypothesis that SS in sparse urine samples accurately represent SS
in the kidney and urine during the time period needed for
formation of human kidney stones. Being a positive result, the
study supports the hypothesis. Naturally, other critical tests of this
hypothesis should be considered and performed, as the hypothesis
is central to the practice of stone prevention at this time.
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